Developer docs
API playgroundTry for free, no card

Search company profiles

Kaida BioPharma

Full company profile

uuid003d1u2

Namestring
Kaida BioPharma
Legal namestring
Kaida BioPharma
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing targeted anti-cancer therapies for treatment-resistant gynecological cancers. Founded in 2022 and headquartered in Fort Lauderdale, Florida, the company is focused on what it terms the "ovarian cancer gap" — patients with recurrent ovarian cancer who have exhausted standard-of-care therapies and have limited durable treatment options. The company operates with 1-10 employees and is privately funded.

Kaida's sole disclosed product candidate is KAD-101, a novel prolactin receptor antagonist that targets prolactin receptor signaling pathways implicated in ovarian cancer progression. The mechanism of action is distinct from standard ovarian cancer treatments, positioning KAD-101 as a differentiated therapeutic approach for the recurrent setting. As of the available data, KAD-101 remains in preclinical development and is being advanced toward first-in-human clinical evaluation. The company has assembled an executive leadership team with experience in clinical development, regulatory affairs, manufacturing, and commercial strategy to support this transition, with Dr. Stella Vnook appointed Acting CEO and Chairperson.

Kaida BioPharma is currently pre-revenue with no commercial products, pricing structures, or distribution channels established. The company raised approximately $1.57M in an early-stage funding round in January 2026 (lead investor undisclosed). Its anticipated future revenue model centers on drug commercialization post-regulatory approval, likely through one-time licensing arrangements and prescription sales via specialty pharmacy channels and hospital formularies. Current go-to-market activity is focused on building relationships with academic medical centers, key opinion leaders, and oncology-focused healthcare institutions to support clinical development partnerships. The company has generated regional visibility through semi-finalist selection in the BIOPITCH competition at the Florida Innovation Conference and finalist selection in the Tampa Tank Pitch Competition, both in November 2025.

Short descriptiontext

Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing KAD-101, a novel prolactin receptor antagonist targeting recurrent ovarian cancer in patients with limited durable treatment options. The company is advancing KAD-101 toward first-in-human clinical evaluation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFort Lauderdale, United States
HQ citystring
Fort Lauderdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ovarian cancer therapy, prolactin receptor antagonist, oncology drug development, gynecological cancer treatment, targeted cancer therapeutics
Industry1 code
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

As an early-stage pharmaceutical company, Kaida BioPharma is pre-revenue and focused on advancing KAD-101 through clinical development. Revenue generation is anticipated through eventual drug commercialization upon regulatory approval, likely via prescription sales through specialty pharmacy channels and hospital formularies.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kaida BioPharma is developing KAD-101, a novel prolactin receptor antagonist candidate intended for the treatment of recurrent ovarian cancer. The company is advancing KAD-101 through preclinical development toward first-in-human clinical evaluation, targeting patients with limited durable treatment options within the 'ovarian cancer gap.' Revenue generation is anticipated through eventual drug commercialization following regulatory approval.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kaida BioPharma is an early-stage pharmaceutical company developing targeted anti-cancer therapies. The company's primary focus is KAD-101, a prolactin receptor antagonist, as its lead product candidate for treating recurrent ovarian cancer. The company is building an executive team to advance this candidate toward first-in-human clinical trials.

Product and service1 record
1KAD-101
CategoryOncology Therapeutics
Description

KAD-101 is the lead prolactin receptor antagonist candidate developed for the treatment of recurrent ovarian cancer in patients with limited durable treatment options. It is currently advancing through preclinical development toward first-in-human clinical evaluation.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

AstraZeneca markets Lynparza (olaparib), the leading PARP inhibitor approved for recurrent ovarian cancer. Broad incumbent defining the standard of care in the indication Kaida is targeting, and a likely strategic partner or acquirer of differentiated mechanisms.

TypeDirect peer
Description

Clovis developed and commercialized Rubraca (rucaparib), a PARP inhibitor for recurrent ovarian cancer. Direct comparable in targeting recurrent ovarian cancer with a novel mechanism, though at a more advanced commercial stage.

TypeDirect peer
Description

Aprea is a clinical-stage oncology company developing therapeutics for ovarian and other cancers. Comparable as a small-cap biotech focused on innovative mechanisms targeting recurrent ovarian cancer, similar in scale and clinical positioning.

TypeBroad incumbent
Description

GSK acquired Tesaro and commercializes Zejula (niraparib), a PARP inhibitor approved for recurrent ovarian cancer. Broad incumbent competitor in the recurrent ovarian cancer treatment landscape, with established commercial infrastructure Kaida will ultimately contend with.

TypeEmerging player
Description

Cardiff Oncology is a clinical-stage biotech developing small-molecule oncology therapies. Comparable as a similarly small, publicly-listed emerging oncology biotech focused on novel mechanisms, providing a relevant benchmark for stage and capital profile.

TypeDirect peer
Description

Mersana is developing antibody-drug conjugates for ovarian cancer and other oncology indications. Comparable as a clinical-stage biotech focused on novel cytotoxic approaches for recurrent ovarian cancer, similar in stage and therapeutic theme to Kaida.

TypeDirect peer
Description

ImmunoGen developed Elahere (mirvetuximab soravtansine), an ADC approved for recurrent ovarian cancer. Direct comparable in the recurrent ovarian cancer space where Kaida is positioning KAD-101, with overlap in patient population and targeting treatment-resistant disease.

TypeEmerging player
Description

Anixa Biosciences is a small clinical-stage biotech pursuing novel oncology therapeutics, including in hormone-driven cancers. Comparable in scale and as an emerging oncology player exploring novel hormone-receptor-adjacent mechanisms, similar to Kaida's prolactin receptor approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kaida BioPharma

Oncology Therapeuticskaida-biopharma.com

Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing KAD-101, a novel prolactin receptor antagonist targeting recurrent ovarian cancer in patients with limited durable treatment options. The company is advancing KAD-101 toward first-in-human clinical evaluation.

What Kaida BioPharma does

Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing targeted anti-cancer therapies for treatment-resistant gynecological cancers. Founded in 2022 and headquartered in Fort Lauderdale, Florida, the company is focused on what it terms the "ovarian cancer gap" — patients with recurrent ovarian cancer who have exhausted standard-of-care therapies and have limited durable treatment options. The company operates with 1-10 employees and is privately funded.

Kaida's sole disclosed product candidate is KAD-101, a novel prolactin receptor antagonist that targets prolactin receptor signaling pathways implicated in ovarian cancer progression. The mechanism of action is distinct from standard ovarian cancer treatments, positioning KAD-101 as a differentiated therapeutic approach for the recurrent setting. As of the available data, KAD-101 remains in preclinical development and is being advanced toward first-in-human clinical evaluation. The company has assembled an executive leadership team with experience in clinical development, regulatory affairs, manufacturing, and commercial strategy to support this transition, with Dr. Stella Vnook appointed Acting CEO and Chairperson.

Kaida BioPharma is currently pre-revenue with no commercial products, pricing structures, or distribution channels established. The company raised approximately $1.57M in an early-stage funding round in January 2026 (lead investor undisclosed). Its anticipated future revenue model centers on drug commercialization post-regulatory approval, likely through one-time licensing arrangements and prescription sales via specialty pharmacy channels and hospital formularies. Current go-to-market activity is focused on building relationships with academic medical centers, key opinion leaders, and oncology-focused healthcare institutions to support clinical development partnerships. The company has generated regional visibility through semi-finalist selection in the BIOPITCH competition at the Florida Innovation Conference and finalist selection in the Tampa Tank Pitch Competition, both in November 2025.

Kaida BioPharma firmographics

Firmographics
Name
Kaida BioPharma
Legal name
Kaida BioPharma
Website
https://kaida-biopharma.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing KAD-101, a novel prolactin receptor antagonist targeting recurrent ovarian cancer in patients with limited durable treatment options. The company is advancing KAD-101 toward first-in-human clinical evaluation.
Ownership category
akta.pro rank

Kaida BioPharma industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Ovarian cancer therapy
  • Prolactin receptor antagonist
  • Oncology drug development
  • Gynecological cancer treatment
  • Targeted cancer therapeutics

Where Kaida BioPharma is headquartered

Location

Headquarters

HQ city
Fort Lauderdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kaida BioPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: As an early-stage pharmaceutical company, Kaida BioPharma is pre-revenue and focused on advancing KAD-101 through clinical development. Revenue generation is anticipated through eventual drug commercialization upon regulatory approval, likely via prescription sales through specialty pharmacy channels and hospital formularies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Kaida BioPharma product offering

Product offering

Core offering

Kaida BioPharma is developing KAD-101, a novel prolactin receptor antagonist candidate intended for the treatment of recurrent ovarian cancer. The company is advancing KAD-101 through preclinical development toward first-in-human clinical evaluation, targeting patients with limited durable treatment options within the 'ovarian cancer gap.' Revenue generation is anticipated through eventual drug commercialization following regulatory approval.

Product overview

Kaida BioPharma is an early-stage pharmaceutical company developing targeted anti-cancer therapies. The company's primary focus is KAD-101, a prolactin receptor antagonist, as its lead product candidate for treating recurrent ovarian cancer. The company is building an executive team to advance this candidate toward first-in-human clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • KAD-101 KAD-101 is the lead prolactin receptor antagonist candidate developed for the treatment of recurrent ovarian cancer in patients with limited durable treatment options. It is currently advancing through preclinical development toward first-in-human clinical evaluation.

Companies that use Kaida BioPharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Kaida BioPharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Kaida BioPharma partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Kaida BioPharma competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: AstraZeneca markets Lynparza (olaparib), the leading PARP inhibitor approved for recurrent ovarian cancer. Broad incumbent defining the standard of care in the indication Kaida is targeting, and a likely strategic partner or acquirer of differentiated mechanisms.
  • GSK (Tesaro legacy): GSK acquired Tesaro and commercializes Zejula (niraparib), a PARP inhibitor approved for recurrent ovarian cancer. Broad incumbent competitor in the recurrent ovarian cancer treatment landscape, with established commercial infrastructure Kaida will ultimately contend with.

Direct peers

  • Clovis Oncology: Clovis developed and commercialized Rubraca (rucaparib), a PARP inhibitor for recurrent ovarian cancer. Direct comparable in targeting recurrent ovarian cancer with a novel mechanism, though at a more advanced commercial stage.
  • Aprea Therapeutics: Aprea is a clinical-stage oncology company developing therapeutics for ovarian and other cancers. Comparable as a small-cap biotech focused on innovative mechanisms targeting recurrent ovarian cancer, similar in scale and clinical positioning.
  • Mersana Therapeutics: Mersana is developing antibody-drug conjugates for ovarian cancer and other oncology indications. Comparable as a clinical-stage biotech focused on novel cytotoxic approaches for recurrent ovarian cancer, similar in stage and therapeutic theme to Kaida.
  • ImmunoGen (now part of AbbVie): ImmunoGen developed Elahere (mirvetuximab soravtansine), an ADC approved for recurrent ovarian cancer. Direct comparable in the recurrent ovarian cancer space where Kaida is positioning KAD-101, with overlap in patient population and targeting treatment-resistant disease.

Emerging players

  • Cardiff Oncology: Cardiff Oncology is a clinical-stage biotech developing small-molecule oncology therapies. Comparable as a similarly small, publicly-listed emerging oncology biotech focused on novel mechanisms, providing a relevant benchmark for stage and capital profile.
  • Anixa Biosciences: Anixa Biosciences is a small clinical-stage biotech pursuing novel oncology therapeutics, including in hormone-driven cancers. Comparable in scale and as an emerging oncology player exploring novel hormone-receptor-adjacent mechanisms, similar to Kaida's prolactin receptor approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Kaida BioPharma social profiles

Digital presence

Kaida BioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kaida BioPharma leadership team

Management profile

Number of profiles

Profiles2 records

Kaida BioPharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kaida BioPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kaida BioPharma

What does Kaida BioPharma do?

Kaida BioPharma is developing KAD-101, a novel prolactin receptor antagonist candidate intended for the treatment of recurrent ovarian cancer. The company is advancing KAD-101 through preclinical development toward first-in-human clinical evaluation, targeting patients with limited durable treatment options within the 'ovarian cancer gap.' Revenue generation is anticipated through eventual drug commercialization following regulatory approval.

Is Kaida BioPharma a public or private company?

Kaida BioPharma is a private company. It is classified as unknown and is currently operating.

When was Kaida BioPharma founded?

Kaida BioPharma was founded in 2022. It employs 1 to 10 people.

Where is Kaida BioPharma based?

Kaida BioPharma is headquartered in Fort Lauderdale, United States, in the North America region.

How does Kaida BioPharma make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are Kaida BioPharma's main competitors?

Broad incumbents on record are AstraZeneca and GSK (Tesaro legacy). Direct peers are Clovis Oncology, Aprea Therapeutics, Mersana Therapeutics and ImmunoGen (now part of AbbVie). Emerging players are Cardiff Oncology and Anixa Biosciences.

Does Kaida BioPharma have an API?

No public API is recorded for Kaida BioPharma.

What industry is Kaida BioPharma in?

Kaida BioPharma's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Applied Clinical TrialsHow to Tell Substance from Branding in Biotech's Support EcosystemStella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, argues that the biotech ecosystem faces a critical funding gap between early-stage programs and later-stage capital sought by large pharmaceutical companies. She advises biotech founders to rigorously evaluate support structures like incubators and accelerators based on track records rather than branding, emphasizing lean development models and early commercialization readiness. The interview highlights shifting clinical development priorities driven by declining NIH funding and the need for capital efficiency.BioSpaceKaida BioPharma Announces Executive Leadership Team to Advance KAD-101, Built for the Ovarian Cancer GapKaida BioPharma announced its executive leadership team and board members to advance KAD-101, its lead prolactin receptor antagonist candidate for recurrent ovarian cancer, toward first-in-human clinical evaluation. The team includes Dr. Stella Vnook as Acting CEO and Chairperson, alongside experienced executives in clinical development, regulatory affairs, manufacturing, and commercial strategy. The company is focused on the 'ovarian cancer gap,' targeting patients with limited durable treatment options.GlobeNewswireKaida BioPharma Announces Executive Leadership Team to Advance KAD-101, Built for the Ovarian Cancer GapKaida BioPharma announced its executive leadership team and board to advance KAD-101, a prolactin receptor antagonist for recurrent ovarian cancer. The company aims to address the ovarian cancer gap where treatment options narrow quickly. KAD-101 is being developed toward first-in-human clinical evaluation.GlobeNewswireKaida BioPharma Appoints Co-Founder Dr. Stella K. Vnook as Chairperson of the BoardKaida BioPharma appointed co-founder Dr. Stella K. Vnook as Chairperson of the Board, aligning leadership with its transition to clinical-stage development. The company is advancing KAD-101, a prolactin receptor antagonist for platinum-resistant ovarian cancer, toward a Phase 1 clinical study.GlobeNewswireKaida BioPharma Selected to Present at Two Upcoming ConferencesKaida BioPharma, an early-stage pharma company developing targeted anti-cancer therapies for hormone-driven cancers affecting women, has been selected to present at two upcoming conferences in November 2025: BIOPITCH at the Florida Innovation Conference in Orlando and Tampa Tank Pitch Competition at the Disrupt the Bay Conference. The company was named a Premier presenter semi-finalist for BIOPITCH for the second consecutive year and a Startup finalist for Tampa Tank, providing opportunities to pitch to top life science investors and industry leaders including Cathie Wood from ARK Invest. Kaida's lead product candidate KAD101 is a growth hormone antagonist designed to block the tumoral PRL/PRLR axis in gynecologic tumors.GlobeNewswireKaida BioPharma Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceKaida BioPharma's co-founder Stella Vnook participated in a virtual investor conference, discussing her dedication and the company's prolactin-targeted cancer therapy. The company's lead product candidate KAD101 blocks the prolactin receptor to induce cell death in gynecologic tumors. The on-demand webcast is available on virtualinvestorco.com.GlobeNewswireKaida BioPharma Chairman and Founding Investor, Craig Pierson, to Present at Opal Group’s Family Office & Private Wealth Management Forum 2025Craig Pierson, Chairman and Founding Investor of Kaida BioPharma, will present on a panel at Opal Group's Family Office & Private Wealth Management Forum 2025 in Newport, RI, July 21-23. The panel, on healthcare investment outlook, will discuss personalized medicine, genomics, telemedicine, and aging populations. Kaida's lead product candidate KAD101 targets prolactin receptor in gynecologic tumors.BioXconomyCrisis as catalyst: From Chernobyl evacuation to biotech innovationVnook, CEO of Likarda, discusses her journey from a Chernobyl refugee to a biotech entrepreneur, highlighting her leadership philosophy and career trajectory in the life sciences sector. She outlines key challenges facing biotech startups, including capital constraints and regulatory hurdles, while emphasizing the importance of agility and strategic resource allocation. The article also details her involvement with various ventures such as Oral BioLife Inc., Kaida Biopharma, and Brainstorm Diagnostics.GlobeNewswireKaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101Kaida BioPharma announced a manufacturing agreement with Northway Biotech for its lead product candidate KAD101, a biologic prolactin receptor antagonist. The partnership will develop a cGMP drug substance batch for clinical studies, with a planned Phase 1 study starting in Q4 2026/Q1 2027.GlobeNewswireKaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101Kaida BioPharma announced a manufacturing agreement with Northway Biotech for its lead product candidate KAD101, a biologic prolactin receptor antagonist. The partnership will develop a cGMP drug substance batch for clinical studies, with a planned Phase 1 study starting in Q4 2026/Q1 2027.